[비즈니스포스트] Yuhan Corporation’s non-small cell lung cancer treatment Lecraza (ingredient name: Lazertinib) will be covered as a first-line treatment in Korea starting next year.
Yuhan Corporation announced on the 27th that Recraza, a treatment for epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer, will be covered by health insurance as a first-line treatment starting January 1, 2024 .
Wookje Cho “A new treatment option”” height=”150″ src=”width=”300″ /> ▲ Yuhan Corporation announced on the 27th that insurance will cover Lecraza as a first-line treatment in Korea starting January 1st from next year. The picture is a picture of a Recraza product. <유한양행>
Accordingly, the Recraza Compassionate Use Program (EAP), which Yuhan Corporation has been running since July this year, will end at the end of this month.
The compassionate use program refers to a pharmaceutical company providing the drug free of charge for compassionate purposes after it has been approved for sale until it is prescribed.
Yuhan Corporation provided the program free of charge to medical institutions across the country that wished to prescribe Rekraza as a first-line treatment. Among domestic new drugs, this is the first time that unlimited drug support is provided free of charge until it is listed on insurance.
Lecraza is the 31st targeted anticancer drug developed in Korea for advanced or metastatic non-small cell lung cancer with a T790M mutation, with confirmed disease progression even after administration of a receptor tyrosine kinase inhibitor adult epithelial cell factor (EGFR-KTI) in January 2021. It is approved for use as a second-line treatment.
Subsequently, this year’s Health Insurance Policy Discussion Committee decided to apply health insurance as the first treatment for epidermal growth factor receptor-stimulating mutation-positive non-small cell lung cancer from January 1 next year, making it it is possible for patients to receive benefits first. and second line treatments I could do it.
This request for reimbursement was made based on clinical efficacy in phase 3 clinical trials for first-line treatments.
Wook-Je Cho, CEO of Yuhan Corporation, said, “We are very pleased that Yuhan Corporation’s Recraza, a new treatment option in the treatment of non-EGFR-mutant lung cancer, which is common in Koreans among lung cancers lung with the highest cancer death rate, has improved access to treatment for patients by expanding coverage for front-line treatment.” He said. Reporter Jang Eun-pa
#Yuhan #Corporations #line #treatment #insurance #start #year #WookJe #Cho #treatment #option
